Literature DB >> 8647778

Increasing ciprofloxacin resistance in salmonellas in England and Wales 1991-1994.

J A Frost1, A Kelleher, B Rowe.   

Abstract

Ciprofloxacin is now widely used as the drug of choice for those severe salmonella infections where antibiotic therapy is indicated. Between 1991 and 1994 ciprofloxacin resistance in salmonellas isolated from humans in England and Wales increased from 0.3% to 2.1%. Among the most prevalent serotypes the highest incidence was seen in Salmonella hadar where ciprofloxacin resistance has increased from 2.0% in 1991 to 39.6% in 1994. The incidence of ciprofloxacin resistance remains uncommon in other serotypes and in 1994 5.1% of Salmonella virchow and Salmonella newport were resistant compared with 1.4% of Salmonella typhimurium and 0.4% of Salmonella enteritidis. There has been a number of examples of development of resistance to quinolone drugs during treatment of human infections. Ciprofloxacin resistance also occurs in salmonellas isolated from food animals and human food. This increasing incidence of ciprofloxacin resistance reflects the more widespread use of fluoroquinolone drugs in both humans and food animals.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8647778     DOI: 10.1093/jac/37.1.85

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

Review 1.  Community acquired infections and bacterial resistance.

Authors:  H Goossens; M J Sprenger
Journal:  BMJ       Date:  1998-09-05

2.  Resistance to ciprofloxacin in pathogenic Enterobacteriaceae in England and Wales in 1996.

Authors:  E J Threlfall; A Graham; T Cheasty; L R Ward; B Rowe
Journal:  J Clin Pathol       Date:  1997-12       Impact factor: 3.411

3.  Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test.

Authors:  A Hakanen; P Kotilainen; J Jalava; A Siitonen; P Huovinen
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

4.  Incidence of quinolone resistance over the period 1986 to 1998 in veterinary Salmonella isolates from Germany.

Authors:  B Malorny; A Schroeter; R Helmuth
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

5.  Use of a LightCycler gyrA mutation assay for rapid identification of mutations conferring decreased susceptibility to ciprofloxacin in multiresistant Salmonella enterica serotype Typhimurium DT104 isolates.

Authors:  R A Walker; N Saunders; A J Lawson; E A Lindsay; M Dassama; L R Ward; M J Woodward; R H Davies; E Liebana; E J Threlfall
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

6.  Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia.

Authors:  A Hakanen; P Kotilainen; P Huovinen; H Helenius; A Siitonen
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

7.  Excess mortality associated with antimicrobial drug-resistant Salmonella typhimurium.

Authors:  Morten Helms; Pernille Vastrup; Peter Gerner-Smidt; Kåre Mølbak
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

8.  Meta-analysis of experimental data concerning antimicrobial resistance gene transfer rates during conjugation.

Authors:  Paul R Hunter; Dawn C Wilkinson; Louise A Catling; Gary C Barker
Journal:  Appl Environ Microbiol       Date:  2008-08-15       Impact factor: 4.792

9.  Fitness costs and stability of a high-level ciprofloxacin resistance phenotype in Salmonella enterica serotype enteritidis: reduced infectivity associated with decreased expression of Salmonella pathogenicity island 1 genes.

Authors:  Edel O'Regan; Teresa Quinn; Jonathan G Frye; Jean-Marie Pagès; Steffen Porwollik; Paula J Fedorka-Cray; Michael McClelland; Séamus Fanning
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

10.  Emerging quinolone-resistant Salmonella in the United States.

Authors:  H Herikstad; P Hayes; M Mokhtar; M L Fracaro; E J Threlfall; F J Angulo
Journal:  Emerg Infect Dis       Date:  1997 Jul-Sep       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.